Clinical trial

Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants

NCT00384059 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed

Key facts

NCT number NCT00384059
Title Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants
Official title A Phase 3, Randomized, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United Kingdom
Lead sponsor Wyeth is now a wholly owned subsidiary of Pfizer, Industry
Status Completed
Phase Phase 3
Study type Interventional
Conditions Vaccines, Pneumococcal
Intervention type Biological
Interventions 13-valent Pneumococcal Conjugate Vaccine, 7vPnC, Pediacel, NeisVac-C, Menitorix
Enrollment 286
Start date Oct 1, 2006
Primary completion Oct 1, 2008
Completion Oct 1, 2008
First posted Oct 4, 2006
Last update posted Jan 24, 2013
Countries United Kingdom

At a glance

  • Yes Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies